LAVA Therapeutics N.V.
LAVA Therapeutics N.V. (LVTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lvtx · stock forecast · 6 analysts (3M) · FMP · updated Feb 3, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$3.75
+115.5% upside
Low
$1.50
Median: $3.75 · Last Close: $1.74
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$3.75
115.5% upside
High Target
$6
244.8%
Low Target
$1.5
-13.8%
Current Price
$1.74
as of today
Based on analyst price targets, the LVTX stock price prediction for the next 12 months ranges from $1.5 to $6. The consensus LVTX price forecast of $3.75 implies 115.5% upside from the current price of $1.74.
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LVTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-05 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-08-05 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-05-15 | JMP Securities | Maintains | Market Perform→Market Perform |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-02-27 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-12-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-12 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2024-12-11 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2024-08-21 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2024-06-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on LAVA Therapeutics N.V. (LVTX) stock. Of the recent 19 rating actions, 0 were upgrades and 4 were downgrades. 6 analysts currently cover LVTX.
Analyst Recommendation Trends
LVTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$17M
↑ 322.8% YoY
Revenue Next Year
$23M
↑ 38.7% YoY
EPS This Year
$-1.39
EPS Next Year
$-0.54
↓ 61.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast LVTX EPS of $-1.39 for the current fiscal year, based on estimates from 1 analysts. The LVTX revenue forecast is $17M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LVTX stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LVTX price target is $3.75 (+115.5% upside), with an analyst consensus of Hold.
LAVA Therapeutics N.V. trades on NASDAQ under the ticker LVTX. The LVTX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
LVTX forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month LVTX price target is $3.75, with a high forecast of $6.00 and a low of $1.50. The median price target is shown in the chart above when available. This implies +115.5% potential upside from the current price of $1.74.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.